This article was originally published in The Gray Sheet
Executive SummaryReceives approval to market the Maverick, the firm's "first peripheral [percutaneous transluminal angioplasty] catheter designed for large blood vessels," Dale Spencer, Scimed president and CEO, reported at the June 15-17 Piper Jaffray conference in Minneapolis. The firm received 510(k) clearance to market the device on May 20. Scimed says that the catheter is suitable for larger vessels located above the knee, as opposed to the firm's Viper, which is indicated for lower-leg vessels. The firm is waiting to accumulate a more broad product line for peripheral vessels before it adopts a "targeted" marketing approach for the Maverick, which sells for between $100 and $200. Scimed also plans to begin clinical trials later this year for a non-PTCA intravascular therapeutic catheter, Spencer said.
You may also be interested in...
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.
At the OurCrowd Global Investor Summit in Jerusalem, Israel, on 13 February, Medtech Insight met wound care device company Nanomedic to find out more about its unique electro-spinning technology.